Who are DE-101 ophthalmic suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anelazol Sodium Enteric-coated Tablets, Azelaic Acid Cream, Sensodyne Sensitivity & Gum, Mesalazine plus Lactobacillus casei, Colchicine Pill, azelaic acid 15% gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/de-101-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

DE-101 ophthalmic suspension — Competitive Intelligence Brief

DE-101 ophthalmic suspension (DE-101 ophthalmic suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory agent. Area: Ophthalmology.

phase 2 Anti-inflammatory agent Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

DE-101 ophthalmic suspension (DE-101 ophthalmic suspension) — Santen Inc.. DE-101 ophthalmic suspension is an anti-inflammatory agent that reduces inflammation in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DE-101 ophthalmic suspension TARGET	DE-101 ophthalmic suspension	Santen Inc.	phase 2	Anti-inflammatory agent
Anelazol Sodium Enteric-coated Tablets	Anelazol Sodium Enteric-coated Tablets	Xuanzhu Biopharmaceutical Co., Ltd.	marketed	Leukotriene inhibitor / Anti-inflammatory agent	Leukotriene synthesis pathway
Azelaic Acid Cream	Azelaic Acid Cream	LEO Pharma	marketed	Topical antimicrobial and anti-inflammatory agent
Sensodyne Sensitivity & Gum	Sensodyne Sensitivity & Gum	HALEON	marketed	Desensitizing toothpaste with antimicrobial and anti-inflammatory agents	Sensory nerve fibers (potassium nitrate); bacterial cell membranes and gum tissue (stannous compounds)
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Colchicine Pill	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
azelaic acid 15% gel	azelaic acid 15% gel	Galderma R&D	marketed	Topical antimicrobial and anti-inflammatory agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory agent class)

Santen Pharmaceutical Co., Ltd. · 2 drugs in this class
Santen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DE-101 ophthalmic suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/de-101-ophthalmic-suspension. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab